<DOC>
	<DOCNO>NCT00655629</DOCNO>
	<brief_summary>This study investigate safety efficacy new dosage form Vardenafil , orodispersible tablet ( ODT ) , compare safety efficacy placebo ( inactive ) tablet treatment erectile dysfunction . After 4-week unmedicated phase , patient receive Vardenafil ODT match placebo 12 week . Safety determine laboratory evaluation . Efficacy determine result different questionnaire patient diary use .</brief_summary>
	<brief_title>Vardenafil Orodispersible Tablet ( ODT ) Versus Placebo Males With Erectile Dysfunction , 50 % Whom Are 65 Years Older .</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Vardenafil Dihydrochloride</mesh_term>
	<criteria>Males 18 yearsofage old . Stable , heterosexual relationship least 6 month . A history erectile dysfunction ( ED ) least 6 month Any underlying cardiovascular condition , include unstable angina pectoris History myocardial infarction , stroke lifethreatening arrhythmia within 6 month prior visit 1 Uncontrolled atrial fibrillation / flutter screen History congenital QT prolongation History surgical prostatectomy due prostate cancer Hereditary degenerative retinal disorder History loss vision NAION ( Nonarteritic anterior ischemic optic neuropathy ) , temporary permanent loss vision Presence penile anatomical abnormality Spinal cord injury Resting postural hypotension hypertension Subjects take nitrate nitric oxide donor , androgen , antiandrogens , alphablockers , HIV ( Human immunodeficiency virus ) protease inhibitor , itraconazole ketoconazole , clarithromycin erythromycin . Subjects take medication know prolong QT interval , Type Ia Type 3 antiarrhythmic . Subjects confirm phenylketonuria ( PKU ) . Use treatment ED within 7 day Visit 1 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Erectile Dysfunction</keyword>
</DOC>